Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing Reactive oxygen species (ROS) generation by cancer cells

The present invention relates to a compound selected from the group consisting of: (2-[(5-benzo[1,3]dioxol-5-yl-1,3,4-oxadiazol-2-yl)sulfanyl]-N-isoxazol-3-yl-acetamide) 5 (Inhibitor No. 3); (3-methoxy-6-(3-{1 -[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-1 H-pyrazol-3-yl}phenyl)pyridazine) (Inhibitor No. 9); (4-[3-(5-amino-1,3,4-oxadiazol-2-yl)isoxazol-5-yl]phenol) (Inhibitor No. 30); (N-[5-(methanesulfonamido)-1,3,4-thiadiazol-2-yl]-6,7,8,9-tetrahydro-5H-carbazole-3- 10 carboxamide) (Inhibitor No. 23); (3-(4-chlorophenyl)sulfonyl-N-(5-isoxazol-5-yl-1,3,4-oxadiazol-2-yl)propanamide) (Inhibitor No. 29); ((2R)-N-(5-isoxazol-5-yl-1,3,4-oxadiazol-2-yl)-2,3-dihydro-1,4-benzodioxine-2-carboxamide) (Inhibitor No. 31); and 15 (3-(benzenesulfonyl)-N-(5-isoxazol-5-yl-1,3,4-oxadiazol-2-yl)propanamide) (Inhibitor No. 32); or a pharmaceutically acceptable salt, solvate or derivative thereof, for use in a method of treatment of a cancer, dysplasia and/or carcinoma in situ through inhibition of ROS generation in the cells of the neoplasm associated with said cancer, dysplasia and/or carcinoma in situ.